Newborn screening for spinal muscular atrophy
Guidelines for Australia and New Zealand
The National Committee for Newborn Screening in Spinal Muscular Atrophy (Australia and New Zealand) are inviting feedback on the following Guideline:
National Recommendations for Newborn Screening in Spinal Muscular Atrophy in Australia and New Zealand.
What is the Guideline about
This Guideline provides advice and information to everyone working to screen, diagnose and care for children and their families through the process of newborn screening for spinal muscular atrophy. This includes for approved providers, service leaders, educators and other staff as well as families with children who screen positive for SMA through newborn screening.
The Guideline has been developed by a range of people who have knowledge and skills in (newborn) screening, diagnosis and clinical care of children with SMA. Importantly the Guideline has been developed with consumer involvement with parents of affected children and patient advocates.
The Guideline is meant to reflect the healthcare journey of a child who screens positive for SMA from newborn screening in Australia and New Zealand. It includes key stages of:
- Screening for SMA
- Diagnosis post screening
- Post diagnosis assessment, care and treatment of children confirmed to have SMA through newborn screening
- Information and support for families
Brief summary
Contact us
Dr Didu (Sandi Kariyawasam) and Professor Michelle Farrar are co-leads of the Guidance Development Group for National Newborn Screening in SMA.